Comparative Pharmacology
Head-to-head clinical analysis: ALOMIDE versus CROMOLYN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOMIDE versus CROMOLYN SODIUM.
ALOMIDE vs CROMOLYN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
1 to 2 drops in each affected eye four times daily (every 6 hours).
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Category C
Category A/B
Mast Cell Stabilizer
Mast Cell Stabilizer